The common adverse effects are increased risk of bleeding (which may be severe) and shortness of breath (dyspnoea). Dyspnoea is usually transient and mild-to-moderate in severity, with a higher risk at 1 month, 1–6 months and >6 months of follow up compared to clopidogrel. Discontinuation of therapy is rare, although some patients do not persist or switch therapies. However, patients should be reassured to continue therapy, as<unk>  does not impact on efficacy and safety with acute coronary syndrome (ACS). Furthermore, there are no associations between dyspnoea and adverse changes in heart and lung function in patients without baseline ACS, heart failure or significant lung disease. Ventricular pauses ≥3 seconds may occur in ACS patients the first week of treatment, but are likely to be mostly asymptomatic and transient, without causing increased clinical bradycardic adverse events. Caution is recommended when using<unk>  in patients with advanced sinoatrial node disease. Allergic skin reactions such as rash and itching have been observed in less than 1% of patients.
Ticagrelor
Clopidogrel
Ticlopidine
Prokarin
Rivaroxaban
Eptifibatide
Apixaban
Palladin